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An Old Dog with New Tricks: 99mTc-
sestamibi SPECT-CT for Differentiation 
of Renal Masses
 80-85% of primary renal 
malignancies
 Relatively more common in 
North America
 Men > Women
 Risk factors include smoking, 
obesity, and hypertension
 Subtypes 
 Clear cell (75-85%)
 Papillary (10-15%)
 Chromophobe (5-10%)
RENAL CELL CARCINOMA (RCC)
Image via 
https://ru.wikipedia.org/wiki/%D0%A4%D0%B0%D0%B9%D0%BB:Re
nal_clear_cell_ca_(1)_Nephrectomy.jpg
 Risk of malignancy decreases with smaller tumor size
 In one study, of the benign resected tumors, 75% were 
oncocytomas and 11% were angiomyolipomas
 Oncocytoma
 Well differentiated neoplastic cells which behave benignly
 Difficult to distinguish from RCC histologically
 Homogenous solid mass, which may have a central scar
 Angiomyolipoma
 Enhancing mass with macroscopic fat and without 
calcification
BENIGN RENAL TUMORS
 Limited ability to distinguish malignant and 
benign solid renal masses on cross-sectional 
imaging
 Limitations of percutaneous renal biopsy: 
Poor negative predictive value 
Tumors incapable of being biopsied
Invasive procedure
DIFFERENTIATION CHALLENGES OF 
RENAL MASSES
 99mTc-sestamibi is a lipophilic cation which 
localizes to cells based on mitochondrial 
content
 Renal oncocytomas have large numbers 
of mitochondria, especially in comparison 
to renal cell carcinoma (RCC) which have 
a relative paucity of mitochondria
 RCCs also often possess drug pumps that 
move 99mTc-sestamibi out of the cells
 As a result, renal oncocytomas 
demonstrate significant radiotracer 
uptake, while RCCs demonstrate limited 
uptake
MECHANISM OF ACTION
Renal Cell Carcinoma
Oncocytoma
 Renal parenchyma displays high 
uptake of 99mTc-sestamibi
 RCCs generally show a distinct 
decrease in radiotracer uptake 
relative to surrounding normal 
parenchyma
 In contrast, oncocytomas display 
uptake that is usually increased or 
similar to that of renal 
parenchyma
 Masses displaying variable 
uptake are likely to be benign if 
any portion displays a moderate 
to high amount of uptake
INTERPRETATION
RCC patterns
Benign patterns
Post contrast T1 fat-saturated MR image shows a 1.6 cm T1 mildly 
hyperintense posterior renal mass concerning for RCC, prompting 99mTc-
sestamibi SPECT-CT
99mTc-sestamibi uptake within the mass is of similar intensity to surrounding renal 
parenchyma, a pattern consistent with a benign renal mass and inconsistent with 
RCC
A photopenic defect is seen over the posteromedial renal mass, this lack of 
any discernable radiotracer uptake indicates that this lesion is unlikely to be 
benign and more likely represents RCC
PITFALLS
 Uptake misrepresentation 
due to respiratory motion
 Inability to distinguish 
radiotracer uptake or lack 
of uptake when evaluating 
smaller lesions
MANAGEMENT ROLE
 Potential to be used instead of 
or in concert with renal biopsy 
for risk stratification of small 
renal masses
 Major benefit in preventing 
kidney resections due to 
benign masses misclassified 
as malignant
 Opportunity for decreased 
morbidity from renal biopsies
